- Filed two patent purposes for lead candidate EL-22, masking muscle loss in overweight sufferers as a monotherapy and together with GLP-1 receptor agonists
- Elevai Biosciences patent portfolio now consists of 4 patent purposes and 5 issued patents that present sufficient safety in focus markets
NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) — Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Firm”), a frontrunner in medical aesthetics, right now introduced the submitting of two novel patent purposes for its lead candidate, EL-22, geared toward treating muscle loss in overweight sufferers. These patent purposes cowl each standalone and mixture therapies utilizing EL-22 alongside GLP-1 receptor agonists, marking a major development in weight problems remedy.
The newly filed patent purposes assist the event of EL-22, an engineered probiotic expressing myostatin, designed to revolutionize weight problems care by preserving muscle mass whereas lowering fats mass. EL-22 has efficiently accomplished a Section 1 medical trial in South Korea, demonstrating security and tolerability in wholesome volunteers. Elevai now plans to evaluate the efficacy of EL-22 together with main weight-loss therapies to deal with muscle losing”a typical aspect impact of GLP-1 drugs”whereas selling fats loss.
Whereas GLP-1 drugs corresponding to Ozempic ®, Wegovy ®, and Mounjaro ® dominate the weight problems market, a important hole stays in preserving lean muscle mass throughout weight reduction, stated Deniel Mero, Co-Founding father of Elevai Biosciences. Muscle mass is significant for metabolism, power, and total mobility, and our patented EL-22 expertise goals to deal with this unmet want with a first-in-class method leveraging myostatin inhibition and oral supply.
The primary patent software, titled Fusion Protein of MYO-2 for Use in Treating Muscle Loss in Overweight Sufferers (Patent Utility Serial No. 18/895,501), focuses on EL-22 as a monotherapy for treating muscle loss in overweight sufferers. The second patent software, Mixture Remedy of a Fusion Protein of MYO-2 with a GLP-1 Receptor Agonist for Treating Muscle Loss in Overweight Sufferers (Patent Utility Serial No. 18/895,519), covers using EL-22 together with GLP-1 receptor agonists, enhancing the advantages of present weight-loss medication by preserving muscle mass.
These patent purposes strengthen Elevai’s mental property portfolio because the Firm advances its mission to remodel the usual of take care of weight problems remedy, with the potential to supply a differentiated remedy that preserves muscle loss, a important part for affected person well being and high quality of life. Elevai Biosciences’ patent portfolio now consists of 4 patent purposes and 5 issued patents that present sufficient safety in focus markets, together with the USA, Japan, China and Korea.
Licensed Product / Nation |
Patent Utility Serial No. |
|
EL-32 USA | 18/627,462 | Pharmaceutical composition for alleviation, remedy, and prevention of sarcopenia containing microorganism remodeled with cell floor show vector operably linked with gene encoding myostatin and activin A proteins as energetic ingredient |
EL-32 Korea | 10-2022-0136606 | A pharmaceutical composition for alleviation, remedy and prevention of sarcopenia containing a microorganism remodeled with a vector expressing myostatin and activin A on the cell floor as an energetic ingredient |
EL-22 USA | 18/895,501 | Fusion Protein of Myo-2 for Use in Treating Muscle Loss in Overweight Sufferers |
EL-22 USA | 18/895,519 | Mixture Remedy of a Fusion Protein of Myo-2 with a GLP-1 Receptor Agonist for Use in Treating Muscle Loss in Overweight Sufferers |
Patent No. | Registration No. | |
EL-22 Korea | 10-0857861-0000 | Floor Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Reworked by Therof |
EL-22 Korea | 10-0872042-0000 | Cell Floor Expression Vector of Myostatin and Microorganisms Reworked Thereby |
EL-22 USA | 8470551 | Floor Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Reworked by Therof |
EL-22 Japan | 5634867 | Floor Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Reworked by Therof |
EL-22 China | ZL200780101116.2 | Floor Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Reworked by Therof |
About Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) makes a speciality of medical aesthetics and biopharmaceutical drug improvement, specializing in improvements for pores and skin aesthetics and coverings tied to weight problems and metabolic well being. The Firm operates a various portfolio of three wholly owned subsidiaries throughout the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Analysis Inc. For extra data please go to www.elevailabs.com.
About Elevai Biosciences
Elevai Biosciences Inc., an Elevai Labs firm, is a biopharmaceutical firm specializing in the event and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic method to deal with weight problems’s urgent situation of preserving muscle whereas on weight reduction remedies, together with GLP-1 receptor agonists. For extra data, please go to www.elevaibio.com.
Ahead-Wanting Statements
Statements contained on this press launch concerning issues that aren’t historic info are forward-looking statements throughout the that means of the Personal Securities Litigation Reform Act of 1995, as amended. Phrases corresponding to believes, expects, plans, potential, would and future or comparable expressions corresponding to look ahead are meant to determine forward-looking statements. Ahead-looking statements are neither historic info nor assurances of future efficiency. As an alternative, they’re based mostly solely on our present beliefs, expectations and assumptions concerning the way forward for our enterprise, future plans and techniques, projections, anticipated occasions and tendencies, the financial system, actions of regulators and future rules and different future situations. As a result of forward-looking statements relate to the longer term, they’re topic to inherent uncertainties, dangers and modifications in circumstances which are tough to foretell and lots of of that are outdoors of our management. Though the Firm believes that the expectations expressed in these forward-looking statements are affordable, it can not guarantee you that such expectations will turn into appropriate, and the Firm cautions buyers that precise outcomes could differ materially from the anticipated outcomes. Due to this fact, you shouldn’t depend on any of those forward-looking statements. These and different dangers are described extra absolutely in Elevai’s filings with the Securities and Change Fee (SEC), together with the Threat Components part of the Firm’s Annual Report on Kind 10-Okay for the yr ended December 31, 2023, filed with the SEC on March 29, 2024, and its different paperwork subsequently filed with or furnished to the SEC. Buyers and safety holders are urged to learn these paperwork freed from cost on the SEC’s web page at www.sec.gov. All forward-looking statements contained on this press launch converse solely as of the date on which they have been made. Besides to the extent required by legislation, the Firm undertakes no obligation to replace such statements to replicate occasions that happen or circumstances that exist after the date on which they have been made.
IR Contact:
IR@ElevaiLabs.com